GlassScriptPhysician profile
Julie A Mcelroy
NPI 1669529483
$1,636.41
in general payments reported to CMS, 2019-2025
14 companies · $597 in 2025
The $597 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $193 · 2021: $83.86 · 2022: $179 · 2023: $232 · 2024: $162 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649 · Long Term Medical Supply Or Device Loan: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.23 |
| Long Term Medical Supply Or Device Loan | $341.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $341.81 | 2025 | Hillrom - Spot Vision Screener |
| Glaxosmithkline, LLC. | $320.67 | 2019-2025 | Bexsero |
| Corium, LLC | $304.26 | 2022-2025 | Azstarys |
| Pfizer INC. | $153.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $151.16 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $67.21 | 2019-2020 | |
| Cranial Technologies, INC | $63.33 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $43.92 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $43.48 | 2025 | |
| Avion Pharmaceuticals | $40.26 | 2023 | Methylphenidate Hydrochloride |
| Sobi, INC | $35.45 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.73 | 2023 | |
| Abbvie INC. | $22.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.